Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00986947 · ClinicalTrials.gov registry record · Phase 2
Desensitization of Highly Sensitized Deceased Donor Renal Transplantation Candidates
A Phase 2 study, sponsored by Johns Hopkins University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT00986947: Clinical Trial Phase 2 study, sponsored by Johns Hopkins University.
NCT00986947 is a Phase 2 study that was terminated before completion, run by Johns Hopkins University. The registered enrollment target is 20 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00986947, a Phase 2 study, was terminated before completion, sponsored by Johns Hopkins University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
Some patients who need kidney transplants have high levels of antibodies that make them incompatible with most potential deceased donor kidney offers. These patients are considered highly-sensitized and are very difficult to transplant because the likelihood that they will receive a compatible organ is very low. There are some medications and procedures that can decrease the antibody levels and this can increase the chance of finding a compatible donor for these patients. In this study the investigators will give two medications (IVIg and Rituximab) to highly-sensitized patients who are on the waiting list for a deceased donor kidney transplant. After the investigators administer these medications, the investigators will continue to check for compatibility as organ offers are received. If a compatible organ offer is received, the investigators will perform the transplant using that organ. The investigators hypothesize that these medications will lower antibody levels and increase the chance that a these patients are able to receive a compatible kidney transplant.
Interventions
- DRUG IVIg and rituximab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2009-09 |
| Est. Completion | 2011-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00986947
The ClinicalTrials.gov registry entry for NCT00986947 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which IVIg and rituximab is the first listed.
NCT00986947 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00986947 about?
NCT00986947 is a clinical study titled "Desensitization of Highly Sensitized Deceased Donor Renal Transplantation Candidates". Some patients who need kidney transplants have high levels of antibodies that make them incompatible with most potential deceased donor kidney offers. These patients are considered highly-sensitized and are very difficult to transplant because the likelihood that they will receive a compatible organ...
What is the current status of trial NCT00986947?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2009-09. Estimated completion is 2011-07.
What interventions are being tested in trial NCT00986947?
The interventions under investigation include: IVIg and rituximab (DRUG).
Who is sponsoring clinical trial NCT00986947?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.